Yahoo · Aug 19, 2026
PolyPid (PYPD) Q2 2026 Earnings Call Transcript
FDA accepts D-PLEX100 application with Priority Review, setting November approval target.
PY
NASDAQ · PYPD
PolyPid Ltd.
Healthcare · Biotechnology
$5.16
Up+$0.05 (+0.97%)
Updated Sep 16, 2026, 10:26 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 40.46M
- P/E ratio
- -1.48
- Dividend yield
- 0.00%
- 52-week range
- $3.06 – $5.73
- Volume
- 81.67K
- Avg. volume
- 80.67K
Price performance
PYPD price history
1M range · 20 trading sessions · Daily adjusted prices
PYPD closed at $5.16 after 20 trading sessions, up 9.09% for the selected period.
- Last close
- $5.16
- Period change
- +9.09%
- Period low
- $4.73
- Period high
- $5.39
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $5.32 | $5.33 | $5.03 | $5.16 | 81.67K |
| Sep 14, 2026 | $5.18 | $5.35 | $5.14 | $5.33 | 180.69K |
| Sep 11, 2026 | $5.20 | $5.24 | $5.04 | $5.15 | 100.18K |
| Sep 10, 2026 | $5.20 | $5.3816 | $5.13 | $5.16 | 69.65K |
| Sep 9, 2026 | $5.22 | $5.39 | $5.16 | $5.20 | 141.58K |
| Sep 8, 2026 | $5.39 | $5.565 | $5.235 | $5.33 | 87.32K |
| Sep 4, 2026 | $5.30 | $5.44 | $5.21 | $5.39 | 73.1K |
| Sep 3, 2026 | $5.36 | $5.36 | $5.20 | $5.27 | 65.92K |
| Sep 2, 2026 | $5.32 | $5.35 | $5.16 | $5.30 | 143.79K |
| Sep 1, 2026 | $5.17 | $5.55 | $5.14 | $5.33 | 242.06K |
| Aug 31, 2026 | $5.08 | $5.15 | $5.00 | $5.14 | 56.03K |
| Aug 28, 2026 | $5.13 | $5.145 | $4.985 | $5.07 | 63.72K |
| Aug 27, 2026 | $5.18 | $5.24 | $5.01 | $5.12 | 78.07K |
| Aug 26, 2026 | $5.07 | $5.23 | $4.96 | $5.11 | 149.34K |
| Aug 25, 2026 | $5.04 | $5.1899 | $5.015 | $5.10 | 139.61K |
| Aug 24, 2026 | $5.12 | $5.18 | $4.97 | $4.985 | 124.42K |
| Aug 21, 2026 | $5.10 | $5.205 | $4.99 | $5.10 | 169.11K |
| Aug 20, 2026 | $5.04 | $5.12 | $4.96 | $5.08 | 129.45K |
| Aug 19, 2026 | $4.78 | $5.08 | $4.6954 | $5.01 | 156.78K |
| Aug 18, 2026 | $4.74 | $4.76 | $4.54 | $4.73 | 123.18K |
Latest PYPD news
The latest Smart Investors Daily articles mentioning PYPD.
Stock researchCompany · Overview
PYPD research
Overview
Company profile and research snapshot.
Company profile
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.00
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 21, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 13, 2025 | Roth Capital | Buy | — |
| Aug 14, 2025 | Craig-Hallum | Buy | — |
| Aug 13, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 12, 2026
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call August 12, 2026 8:30 AM EDTCompany ParticipantsDikla Akselbrad - CEO & DirectorOri Warshavsky - Chief...
Benzinga · Aug 12, 2026
PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 55.13 percent increase over losses of $(0.78) per share from the same
Benzinga · Jul 29, 2026
PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28
The FDA did not identify any filing review issues and set a Prescription Drug User Fee Act ("PDUFA") target action date of November 28, 2026, approximately one quarter ahead of the Company’s previously
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
